Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference

Rhea-AI Summary

Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company, announced a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 12:00 PM ET. The event aims to discuss the company’s innovative approaches in developing therapeutics for immune-mediated diseases.

The company’s lead candidate, PRA023, is an IgG1 humanized monoclonal antibody targeting TL1A, showing promise for conditions like ulcerative colitis and Crohn’s Disease. A live and archived webcast will be available on the Prometheus Biosciences investor page.

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today announced that management will conduct a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 12:00 PM ET.

A live and archived webcast of the fireside chat will be available via the Events & Webcasts page on the Investor section of the Prometheus Biosciences website.

About Prometheus Biosciences

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases. The Company’s target discovery engine, Prometheus360™, combines proprietary machine learning-based analytical approaches with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.

The Company’s lead candidate, PRA023, is an IgG1 humanized monoclonal antibody that has been shown to block tumor necrosis factor (TNF)-like ligand 1A (TL1A). PRA023 binds both soluble and membrane-associated human TL1A with high affinity and specificity and has the potential to substantially improve outcomes for moderate-to-severe IBD patients predisposed to increased TL1A expression. Prometheus is developing PRA023 for the treatment of immune-mediated diseases including ulcerative colitis (UC), Crohn’s Disease (CD), and systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Prometheus Biosciences Contact:
Noel Kurdi
VP Investor Relations and Communications
(646) 241-4400
nkurdi@prometheusbiosciences.com

Media contact:
Juniper Point
Amy Conrad
(858) 914-1962
media@prometheusbiosciences.com

FAQ

When is Prometheus Biosciences' fireside chat at the SVB Securities Global Biopharma Conference?

The fireside chat will take place on February 14, 2023, at 12:00 PM ET.

What is the focus of Prometheus Biosciences' presentation at the conference?

The presentation will discuss the company's precision medicine approach to developing therapeutics for immune-mediated diseases.

What is PRA023 and its significance for Prometheus Biosciences?

PRA023 is an IgG1 humanized monoclonal antibody that targets TL1A, which may improve outcomes for patients with moderate-to-severe IBD.

How can I access the webcast of the Prometheus Biosciences fireside chat?

You can access the live and archived webcast via the Events & Webcasts page on the Prometheus Biosciences website.

What diseases is Prometheus Biosciences targeting with PRA023?

Prometheus Biosciences is developing PRA023 for ulcerative colitis, Crohn’s Disease, and systemic sclerosis-associated interstitial lung disease.